knowledge -WSS

knowledge

author：focus 2025-09-30 12:40:58 - browse：3686

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： A strong 6.5

WSS

Medical students need to learn the potent medicine of empathy

More hospitals are billing patients as online messages surge

Congress: Prevent baby formula shortages by passing a new bill

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Should insurance cover cosmetic surgery?

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

hotspot

knowledge

focus

Guidelines to prevent youth baseball injuries need more muscle

Study: Hearing aids may slow cognitive decline in those at risk

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Affirmative action in medical school literally saved lives

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Psychedelics group wrestles with new pharma identity

Decentralized clinical trials need collaboration to achieve wider use

23andMe had bad news about my health. I wish a person had delivered it

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

focus

ER docs worry over extreme heat as a 'mass casualty event'

Medical students need to learn the potent medicine of empathy

Twill hunts for pharma partner to market its depression app

The world needs the new pandemic treaty

FDA seeking to stop procedures at two unregulated stem cell clinics

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

focus

knowledge

knowledge

knowledge